An Innovative Approach
Synspira’s innovative and proprietary glycochemistry technology platform is designed to target and change the course of progressive pulmonary diseases and life-threatening pulmonary conditions.
In a normal lung, thin, watery mucus lines the lung surface, allowing structures known as cilia to move freely and aid in the clearance of bacteria and particles from the lung.
During pulmonary infection and disease states such as cystic fibrosis (CF), the mucus lining the lung surface becomes thick and viscous. This thick mucus impedes movement of the cilia and reduces their ability to clear mucus and bacteria from the lung, allowing for the bacteria to spread. Bacterial proliferation increases the buildup of biofilms on the lung’s surface. These biofilms can serve as a barrier through which antibiotics cannot penetrate, thereby protecting the bacteria and rendering antibiotics less effective against the infection, increasing the potential for the development of antibiotic resistance. Bacteria in biofilms become tolerant to antibiotics, components of both the innate and adaptive immune response, and resist phagocytosis. The persistence of these biofilm infections within the lung leads to the development of a distinct antibody response prompting chronic inflammation mediated by granulocytes, and results in severe damage to the lung tissue.
Synspira’s molecules are designed to disrupt the cohesion of bacterial biofilms to expose the bacteria to antibiotic treatment and to thin and loosen mucus to allow cilia to move freely and assist in clearing bacteria and mucus from the lung surface. The compounds also interact with the cell walls of invading bacteria to increase their permeability, reduce their viability and potentiate the efficacy of antibiotics.